Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic …
WEBSep 15, 2024 · Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) after previous chemotherapy.
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic …
WEBTrastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) after previous chemotherapy. Methods: We conducted a phase 3, multicenter, open-label trial involving patients with hormone receptor-positive metastatic breast cancer with low …
Enhertu - European Medicines Agency (EMA)
WEBDec 11, 2020 · deruxtecan is a toxic substance that kills cells when they attempt to divide and grow. It becomes active once the trastuzumab component has attached to HER2 and enters the cancer cell. Deruxtecan blocks an enzyme called topoisomerase I which is involved in copying cell DNA needed to make new cells.
Trastuzumab Deruxtecan in Previously Treated HER2-Low …
WEBJun 5, 2022 · Trastuzumab deruxtecan (formerly DS-8201), an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload through a...
NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine …
WEBSep 14, 2024 · In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting....
Safety and efficacy of trastuzumab deruxtecan for metastatic …
WEBMay 29, 2024 · The efficacy outcomes demonstrated significant heterogeneity, which was addressed through sensitivity analysis. Conclusions: T-DXd shows significant efficacy in treating metastatic HER2+ and HER2-low breast cancer, offering a valuable therapeutic option for patients with advanced disease.
Real-World Outcomes of Trastuzumab Deruxtecan in Patients …
WEBNov 23, 2023 · Trastuzumab deruxtecan (T-DXd) demonstrated unprecedented efficacy in patients with pretreated HER2+ metastatic breast cancer (mBC). However, few data are available about its efficacy in routine clinical practice.
T-DXd Effective in Some With HER2+ Breast Cancer - Medscape
WEBSep 15, 2024 · For patients without brain metastases, the ORR was 62.7% (95% CI, 56.5% - 68.8%), which, according to Lin, "aligns with previous phase 3 trastuzumab deruxtecan trials in this setting."
Trastuzumab deruxtecan in HER2-positive advanced breast …
WEBSep 13, 2024 · Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or retrospective patient cohorts with human epidermal growth factor receptor 2–positive (HER2+) advanced ...
Trastuzumab deruxtecan in HER2-positive breast cancer with …
WEBAug 8, 2022 · Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We conducted the...
Skip to content